Símbolo: LLY

Eli Lilly

Farmacêutico Saúde Fabricantes de medicamentos - geral

Preço 1222.61

Rec. Comprar Potencial 83 Risco 28 Atualizado 2026-07-27

Site oficial

Impacto da previsão

positivo

Alvo +13.3% preenchimento do alvo 88.3%

Reação D5 +0.63% · D10 +2.64% recente confirmado · confiança do mercado

Impacto Potencial +6 · Risco -3 válido até 2026-08-13

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B Minha compra S Minha venda

Descrição

Empresa e modelo de negócios

A Eli Lilly é uma empresa global de saúde que se concentra na descoberta, desenvolvimento e comercialização de produtos farmacêuticos. Seus produtos principais incluem tratamentos para diabetes, oncologia, imunologia e doenças neurodegenerativas. Os principais segmentos de negócios consistem em cuidados com diabetes, oncologia e neurociência, com receita significativa gerada a partir de produtos de insulina e terapias contra o câncer. A empresa é reconhecida por seu pipeline inovador de medicamentos e forte presença no mercado de saúde.

Perfil de investimento

As ações da Eli Lilly são posicionadas como um investimento equilibrado, atraente para investidores que buscam crescimento moderado e alguma renda por meio de dividendos. A empresa demonstra crescimento de receita estável e um rendimento de dividendos consistente, tornando-a adequada para aqueles que procuram uma combinação de valorização de capital e renda. Sua presença de mercado estabelecida e o desenvolvimento contínuo de produtos contribuem para um perfil de risco-retorno favorável.

Categoria: Farmacêutico Setor: Saúde Indústria: Fabricantes de medicamentos - geral Estilo de investimento: Crescimento Horizonte: Longo prazo Tipo de empresa: Blue Chip Tipo de empresa: Líder de mercado Experiência: Básico

Métricas fundamentais (experimental) Atualizado: 2026-07-29

EPS (TTM) — lucro por ação dos últimos 12 meses, $: 28.20
Receita QoQ — crescimento da receita trimestre contra trimestre: 2.6%
Surpresa de EPS: 22.7%
Volatilidade 20d: 1.6%
Dividend yield: 0.7%
última data ex-dividendo: 2026-08-14

Mudanças na recomendação da IA

Data	Antes	Depois	Motivo
2026-05-18	Manter	Comprar	Strong fundamentals and positive short-term momentum.
2026-05-10	Comprar	Manter	Weak momentum and high risk; mixed analyst signals.
2026-05-08	—	Comprar	Solid fundamentals but mixed momentum signals.
2026-05-08	Comprar	Comprar	Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29	Manter	Comprar	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17	Comprar	Manter	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09	Manter	Comprar	Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22	Comprar	Manter	Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06	Manter	Comprar	Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29	Comprar	Manter	Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.

Previsões de analistas

Data	Analista	Action	Alvo	Preço na época
2026-07-14	Bernstein	Preço-alvo elevado	— → 1385	1185.08
2026-07-13	UBS	Preço-alvo elevado	1250 → 1425	1189.91003
2026-07-13	Guggenheim	Preço-alvo elevado	— → 1273	1188.58
2026-07-09	UBS	Preço-alvo elevado	1281 → 1370	1222.125
2026-07-08	Truist Financial	Preço-alvo elevado	— → 1370	1227.07
2026-07-08	RBC Capital	Preço-alvo elevado	1250 → 1500	1229.21997
2026-07-08	Morgan Stanley	Preço-alvo elevado	1344 → 1347	1235.56
2026-07-06	Cantor Fitzgerald	Preço-alvo elevado	— → 1350	1210.5
2026-06-25	Leerink Partners	Preço-alvo elevado	1119 → 1232	1117.26
2026-06-22	Berenberg Bank	Preço-alvo elevado	1050 → 1135	1111.67
2026-06-09	Jefferies	Preço-alvo elevado	1330 → 1350	1143.35
2026-05-26	HSBC	Preço-alvo elevado	— → 1251	1065
2026-05-26	Leerink Partners	Atualizar	— → 1119	1065
2026-05-21	Wolfe Research	Preço-alvo elevado	1325 → 1350	1037.82007
2026-05-05	Barclays	Preço-alvo elevado	1350 → 1400	967.93
2026-05-01	Morgan Stanley	Preço-alvo elevado	1327 → 1344	961.555
2026-05-01	Cantor Fitzgerald	Preço-alvo elevado	1205 → 1230	970.675
2026-04-10	Morgan Stanley	Preço-alvo elevado	1313 → 1327	939.31
2026-03-13	Jefferies	Atualizar	— → 1300	1000.78003
2026-03-06	Deutsche Bank	Atualizar	— → 1285	990.31
2026-03-05	Morgan Stanley	Atualizar	— → 1313	972.5

Notícias Página 3 de 4

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

06/08/2026, 10:48 AM business review healthcare Novo Nordisk Eli Lilly

Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.

Stock Market Experiences Significant Decline Following Strong Jobs Report and Disappointing Earnings from Tech Companies

06/06/2026, 10:32 AM economy review tech semiconductors SpaceX Wells Fargo Intel Broadcom Eli Lilly

Last week's stock market experienced a significant downturn, primarily driven by disappointing earnings from major tech companies and a strong jobs report that diminished expectations for a Federal Reserve interest rate cut. This shift has raised concerns about the sustainability of recent market highs and the potential impact of increased stock supply from upcoming IPOs.

Cramer Highlights Buying Opportunity in AI Stocks Amid Market Cooling

06/05/2026, 10:33 AM economy review ai tech CrowdStrike Holdings SpaceX Cardinal Health Intel Johnson & Johnson Apple Broadcom Eli Lilly

The recent decline in stock prices, particularly in the tech sector, presents a potential buying opportunity for investors, especially in chip stocks and AI-related companies, according to Jim Cramer.

Dow Jones Industrial Average Hits Record High as Health-Care Stocks Lead Market Gains

06/05/2026, 05:34 AM business review healthcare UnitedHealth Humana Centene Eli Lilly

Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.

Jim Cramer Suggests Trimming Goldman Sachs (GS) and Wells Fargo (WFC) Positions for Different Reasons

06/04/2026, 09:31 AM economy review finance CrowdStrike Holdings Goldman Sachs Wells Fargo Johnson & Johnson Eli Lilly

Investors are witnessing a sector rotation from AI hardware to healthcare and financials, with notable movements in stocks like Goldman Sachs and CrowdStrike, indicating shifting market dynamics.

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

06/03/2026, 04:33 AM business announcement healthcare Eli Lilly

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.

Analysts JPMorgan recommend top stocks for June, including Viasat (VSAT) and Eli Lilly (LLY)

06/02/2026, 08:31 AM investing recommendation Analysts: analysts, JPMorgan software telecom Viasat Eli Lilly

JPMorgan's updated list of top investment ideas for June highlights strong performance in U.S. stocks, particularly in technology, and includes new recommendations such as Viasat, which has seen significant growth despite recent volatility.

CVS Health to Restore Coverage of Eli Lilly’s Zepbound and Add Foundayo Obesity Pill to Drug Plans

05/28/2026, 04:34 AM business announcement healthcare CVS Health Eli Lilly

CVS Health's decision to restore coverage for Eli Lilly's Zepbound and add its new obesity pill Foundayo is significant as it enhances patient access to weight loss treatments and strengthens Lilly's competitive position against Novo Nordisk in the market.

Stocks to Watch: AutoZone Declines on Sales Challenges, Eli Lilly Acquires Three Companies, Ferrari Launches Electric Vehicle, and Lear Upgraded by TD Cowen

05/26/2026, 05:34 AM business review auto pharma Micron Advanced Micro Devices Exxon Mobil Intuitive Machines AutoZone Ferrari Chevron Qualcomm Eli Lilly

Several companies are experiencing notable stock movements ahead of the market opening, with AutoZone facing declines due to disappointing international sales, while Eli Lilly's acquisition strategy boosts its stock.

Eli Lilly (LLY) Plans Nearly $4 Billion in Vaccine Acquisitions to Expand Infectious Disease Research

05/26/2026, 05:34 AM announcement healthcare Eli Lilly

Eli Lilly's announcement to acquire three companies for nearly $4 billion highlights its strategic shift towards infectious disease research, which could enhance its market position in vaccine development.